Considering the signaling cascade of RANKL-RANK and its role in osteoclast differentiation, the application of denosumab (human anti-RANKL mAb) in clinical therapies for osteoporosis and the validation of a novel peptide which targets RANKL is theoretically possible. This evidence concerns the gene TNFSF11 and osteoporosis.